Syndax Pharmaceuticals (SNDX) PT Set at $5.00 by Morgan Stanley

Morgan Stanley set a $5.00 target price on Syndax Pharmaceuticals (NASDAQ:SNDX) in a research report report published on Friday morning. The firm currently has a hold rating on the stock.

SNDX has been the topic of a number of other reports. B. Riley initiated coverage on Syndax Pharmaceuticals in a research report on Tuesday, January 8th. They set a buy rating and a $40.00 target price on the stock. Robert W. Baird started coverage on Syndax Pharmaceuticals in a research report on Friday, January 4th. They set an outperform rating on the stock. Zacks Investment Research lowered shares of Syndax Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, November 20th. Finally, ValuEngine lowered shares of Syndax Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, February 4th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $14.07.

NASDAQ:SNDX opened at $5.24 on Friday. Syndax Pharmaceuticals has a 52 week low of $3.39 and a 52 week high of $15.20. The stock has a market cap of $133.87 million, a PE ratio of -1.81 and a beta of 2.38.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Thursday, March 7th. The company reported ($0.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.02). Syndax Pharmaceuticals had a negative net margin of 3,185.75% and a negative return on equity of 91.11%. The business had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. Analysts predict that Syndax Pharmaceuticals will post -2.89 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of SNDX. 683 Capital Management LLC lifted its stake in Syndax Pharmaceuticals by 157.7% in the 4th quarter. 683 Capital Management LLC now owns 1,342,839 shares of the company’s stock valued at $5,976,000 after buying an additional 821,839 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Syndax Pharmaceuticals by 42.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 795,767 shares of the company’s stock valued at $6,428,000 after buying an additional 237,042 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Syndax Pharmaceuticals by 560.3% in the 3rd quarter. Renaissance Technologies LLC now owns 279,300 shares of the company’s stock valued at $2,257,000 after buying an additional 237,000 shares in the last quarter. Sofinnova Investments Inc. lifted its stake in Syndax Pharmaceuticals by 102.2% in the 4th quarter. Sofinnova Investments Inc. now owns 350,110 shares of the company’s stock valued at $1,558,000 after buying an additional 176,998 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Syndax Pharmaceuticals by 289.7% in the 4th quarter. Bank of America Corp DE now owns 229,091 shares of the company’s stock valued at $1,019,000 after buying an additional 170,305 shares in the last quarter. 61.41% of the stock is currently owned by hedge funds and other institutional investors.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

Recommended Story: Terms to Better Understand Call Options

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.